Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of Directors
NATICK, Mass., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the appointment of Garen Bohlin to its board of directors, effective immediately. Mr. Bohlin has held senior executive positions among biotechnology companies for almost 30 years.
Help employers find you! Check out all the jobs and post your resume.